Moderna
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2010-01-01
- Employees
- 5.6K
- Market Cap
- $30.3B
- Website
- http://www.modernatx.com
- Introduction
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.
A Phase 1/2, adaptive, open-label, single ascending dose to multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of mRNA-3745 in participants with glycogen storage disease type 1a (GSD1a), followed by an open-label extension
- First Posted Date
- 2024-05-27
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Moderna Therapeutics Inc.
- Target Recruit Count
- 24
- Registration Number
- 2022-502963-39-00
- Locations
- 🇪🇸
Hospital Universitario 12 De Octubre, Madrid, Spain
🇪🇸Hospital Universitario Regional De Malaga, Malaga, Spain
🇫🇷Hopital Antoine Beclere, Clamart, France
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age
- Conditions
- Cytomegalovirus Infection
- Interventions
- Biological: Placebo
- First Posted Date
- 2021-10-20
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 7454
- Registration Number
- NCT05085366
- Locations
- 🇺🇸
Central Research Associates Inc, Birmingham, Alabama, United States
🇺🇸Accel Research Site - Achieve - Birmingham - ERN - PPDS, Birmingham, Alabama, United States
🇺🇸SEC Clinical Research LLC - Dothan - ClinEdge - PPDS, Dothan, Alabama, United States
A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine
- First Posted Date
- 2021-07-26
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 291
- Registration Number
- NCT04975893
- Locations
- 🇺🇸
Optimal Research, LLC, Peoria, Illinois, United States
🇺🇸Johnson County Clin-Trials, Inc., Lenexa, Kansas, United States
🇺🇸Alliance for Multispeciality Research, LLC, Lexington, Kentucky, United States
Post-Marketing Safety Study of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in the United States
- Conditions
- SARS-CoV-2
- First Posted Date
- 2021-07-12
- Last Posted Date
- 2023-07-17
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 50000000
- Registration Number
- NCT04958954
- Locations
- 🇺🇸
Aetion Inc., New York, New York, United States
Moderna COVID-19 Vaccine mRNA-1273 Observational Pregnancy Outcome Study
- Conditions
- SARS-CoV-2
- First Posted Date
- 2021-07-12
- Last Posted Date
- 2023-11-28
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT04958304
- Locations
- 🇺🇸
IQVIA Call Center for United States and Canada, Durham, North Carolina, United States
A Study of mRNA-1010 Seasonal Influenza Vaccine in Healthy Adults
- Conditions
- Seasonal Influenza
- Interventions
- Biological: mRNA-1010Biological: PlaceboBiological: Active Comparator
- First Posted Date
- 2021-07-09
- Last Posted Date
- 2023-10-27
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 885
- Registration Number
- NCT04956575
- Locations
- 🇺🇸
Cognitive Clinical Trials - Phoenix, Phoenix, Arizona, United States
🇺🇸Alliance for Multispecialty Research, LLC - Phoenix, Tempe, Arizona, United States
🇺🇸Benchmark Research - Colton, CA, Colton, California, United States
Long-Term Follow-up Survey of COVID-19 Vaccine After Vaccination
- Conditions
- Coronavirus Disease (COVID-19)
- Interventions
- Biological: COVID-19 Vaccine
- First Posted Date
- 2021-06-28
- Last Posted Date
- 2023-05-19
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 8538
- Registration Number
- NCT04941144
- Locations
- 🇯🇵
Moderna selected site, Tokyo, Japan
A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 (COVID-19) Variants
- Conditions
- SARS-CoV-2
- Interventions
- First Posted Date
- 2021-06-15
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 5161
- Registration Number
- NCT04927065
- Locations
- 🇺🇸
Benchmark Research (California), Sacramento, California, United States
🇺🇸Research Centers of America, Hollywood, Florida, United States
🇺🇸Jacksonville Center For Clinical Research, Jacksonville, Florida, United States
A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus Areas
- First Posted Date
- 2021-06-08
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 808
- Registration Number
- NCT04917861
- Locations
- 🇺🇸
Meridian Clinical Research (Sioux City, IA), Sioux City, Iowa, United States
🇺🇸Johnson County Clin-Trials, Lenexa, Kansas, United States
🇺🇸Benchmark Research - Fort Worth, Fort Worth, Texas, United States
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-6231 in Healthy Adults
- First Posted Date
- 2021-06-07
- Last Posted Date
- 2022-08-10
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT04916431
- Locations
- 🇦🇺
Nucleus Network Limited, Melbourne, Victoria, Australia